Activity 3: Characterization of Aß and alfa-synuclein oligomers

Background/Aim:

A common denominator for neurodegenerative disorders is the pathological accumulation of proteins with an altered conformation, either within or between neurons of the affected brain regions. In Alzheimer’s disease (AD), Aß-peptides deposit in the parenchyma and vessel walls of the brain. Due to its hydrophobic nature Aß-monomers gradually aggregate and form larger soluble molecular species (oligomers/protofibrils), which eventually result in deposition of insoluble fibrils as senile plaques. Moreover, in dementia with Lewy bodies (DLB), the second most common dementia disorder, the alfa-synuclein protein aggregates and forms intracellular inclusions (Lewy bodies and Lewy neurites) in widespread cortical areas of the brain. These intracellular inclusions are also present in the brains of Parkinson’s disease (PD) as well as in a subtype of AD.

The aim of this activity is to learn more about the soluble aggregates of Aß and alfa-synuclein and to develop visual and quantitative assays for these aggregates. Such assays will be applied to evaluate the diagnostic value for these species.

 

 

 

Project leader:

 

 

 

Participants:

  • Frida Ekholm Pettersson (UU)
  • Joakim Bergström (UU)
  • Sofia Söllvander (UU)
  • Thomas Näsström (UU)
  • Dag Sehlin (UU)
  • Fredrik Nikolajeff (UU)
  • Mikael Karlsson (UU)
  • Mats Inganäs (Gyros)

 

 

PARTNERS
Uppsala Berzelii Technology Centre for Neurodiagnostics | Email info@berzelii.uu.se